论文部分内容阅读
目的探讨匹多莫德、孟鲁司特及甲强龙辅治肺大叶实变性重症支原体肺炎的临床疗效。方法选取2013年1月-2014年12月医院收治的肺大叶实变性重症支原体肺炎患者100例,将其随机分为观察组与对照组各50例。对照组予化痰、止咳、平喘等对症治疗,并予阿奇霉素治疗;观察组在对照组基础上联合匹多莫德、孟鲁司特及甲强龙进行治疗,观察、比较2组患者的咳嗽持续时间、退热时间及住院时间等。结果观察组总有效率为100.0%明显高于对照组的82.0%,差异有统计学意义(P<0.05)。观察组咳嗽消除时间、退热时间与住院时间均较对照组短,差异有统计学意义(P<0.05)。结论匹多莫德、孟鲁司特及甲强龙辅治肺大叶实变性重症支原体肺炎临床效果显著,安全性高,不良反应小,值得临床推广应用。
Objective To investigate the clinical efficacy of pidotimod, montelukast and methylprednisolone in the treatment of severe mycoplasma pneumonia with large lobar degeneration. Methods A total of 100 patients with severe mycoplasma pneumonia who were admitted to our hospital from January 2013 to December 2014 were randomly divided into observation group (50 cases) and control group (50 cases). The patients in the control group were given symptomatic treatment of phlegm, cough and asthma, and were treated with azithromycin. The observation group was treated with Pidotimod, montelukast and methylprednisolone on the basis of the control group. The patients in the two groups were compared Cough duration, antipyretic time and hospital stay. Results The total effective rate was 100.0% in the observation group was significantly higher than 82.0% in the control group, the difference was statistically significant (P <0.05). The observation group cough elimination time, fever and hospital stay shorter than the control group, the difference was statistically significant (P <0.05). Conclusion Pidotimod, montelukast and methylprednisolone adjuvant treatment of large lobar degeneration severe mycoplasma pneumonia clinical effect is significant, high safety, adverse reactions, it is worth promoting the clinical application.